The company sells clinically validated anti-ageing products for hair, skin and body.
Showing 25 of 1796
The partially underwritten issue closed earlier this month and raised $18.96 million.
Bronchitol works by rehydrating the airway/lung surface and promoting a productive cough. It is used for the treatment of cystic fibrosis patients.
The trial met the primary endpoint with a change in the knee injury and OA outcome score, confirming the potential for safe and effective treatment with iPPS.
The company can raise an additional $1.2 million by placing the shortfall within three months.
Aridol is a lung function test designed to help doctors diagnose and manage asthma.
The company sells anti-ageing products for hair, skin and body.
Patients access the treatment through their doctor under the TGA’s Special Access Scheme.
Dr Kiran Bhirangi has a deep knowledge of international regulatory and reimbursement environments, having worked across device development, launch and evaluation.
The patent was granted by the State Intellectual Property Office of China.
The readout of clinical trials is expected this month.
Paradigm is focused on repurposing the drug pentosan polysulfate sodium in its injectable form (iPPS) for orthopaedic treatment of OA and bone marrow edema lesions (BMEL).
The readout of clinical trial results is expected in December.
Shareholders can subscribe for new shares or transfer their entitlements.
The Australian regenerative medicine company is developing a portfolio of innovative cellular therapies targeting significant unmet medical needs with a licence-driven strategy.
An exclusive licence agreement has been executed with the Icahn School of Medicine at Mount Sinai, New York.
Pharmaxis is the first company to progress a small molecule LOX inhibitor into clinical development.
The first commercial shipment is expected to arrive this month.
The company’s capital position now stands at $10.5 million which provides for the preparation of regulatory filings.
There were no adverse safety findings and excellent drug-like properties were confirmed for the second of the LOXL2 inhibitor compounds.
The voluntarily-suspended company is progressing an ongoing recapitalisation plan.
The company’s managing director continues to welcome new investment subscriptions.
The company's patent portfolio comprises 60 patents and applications in 13 patent families.
Cellmid is now focused on implementing a cost-effective experiential marketing solution.
Legalisation for the recreational use of cannabis in Canada on October 17, 2018, will result in the accelerated growth of this nascent industry.